Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967559 | 0.80 | KIF11 (0.49) | CYP11B1CYP11B2ALDH1A1KDM4EAR | |
| SCHEMBL16649161 | 0.79 | CYP11B1 (0.46) | CYP11B1CYP11B2ALDH1A1PKMTRPM8 | |
| SCHEMBL16139574 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2ALDH1A1TRPM8KDM4E | |
| SCHEMBL2634852 | 0.78 | ALDH1A1 (0.49) | CYP11B1CYP11B2ALDH1A1PKMKDM4E | |
| SCHEMBL582977 | 0.78 | ALDH1A1 (0.46) | CYP11B1CYP11B2ALDH1A1TRPM8KDM4E | |
| SCHEMBL30055347 | 0.78 | ALDH1A1 (0.49) | CYP11B1CYP11B2ALDH1A1PKMKDM4E | |
| SCHEMBL28641181 | 0.74 | ALDH1A1 (0.47) | ALDH1A1PKMKDM4EMEN1KMT2A | |
| SCHEMBL1498826 | 0.74 | ALDH1A1 (0.43) | ALDH1A1TRPM8KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL24147640 | 0.74 | AGBL2 (0.40) | CYP11B1CYP11B2ALDH1A1TRPM8KDM4E | |
| SCHEMBL10460598 | 0.74 | CYP1A2 (0.40) | CYP11B1CYP11B2ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7566726-B2 | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity | MERCK & CO. INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1592689-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7410961-B2 | 2,6-disubstituted piperiddines as modulators | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7393844-B2 | Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| EP-1746997-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CZCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| WO-2005115392-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-4931452-A | N-cyanomethyl-2-pyridinone insecticides | THE DOW CHEMICAL COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| WO-1989004301-A1 | N-CYANOMETHYL-2-PYRIDINONE INSECTICIDES | THE DOW CHEMICAL COMPANY (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0316185-A2 | N-cyanomethyl-2-pyridinone insecticides | THE DOW CHEMICAL COMPANY (US) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | CYP11B1 2824/4885CYP11B2 2701/4885ALDH1A1 686/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | CYP11B1 725/4885CYP11B2 1133/4885ALDH1A1 1954/4885 |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | CYP11B1 712/4885CYP11B2 567/4885ALDH1A1 2646/4885 |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CYP11B1 344/4885CYP11B2 350/4885ALDH1A1 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.